Schistosoma mansoni antigen Sm-p80: Prophylactic efficacy of a vaccine formulated in human approved plasmid vector and adjuvant (VR 1020 and alum).
about
Schistosomiasis vaccinesPreclinical prophylactic efficacy testing of Sm-p80-based vaccine in a nonhuman primate model of Schistosoma mansoni infection and immunoglobulin G and E responses to Sm-p80 in human serum samples from an area where schistosomiasis is endemicEffect of vaccine administration modality on immunogenicity and efficacy.Complement plays a minimal role in Sm-p80-mediated protection against Schistosoma mansoni.Dynamics of Th17 cells and their role in Schistosoma japonicum infection in C57BL/6 mice.Sm-p80-based schistosomiasis vaccine mediated epistatic interactions identified potential immune signatures for vaccine efficacy in mice and baboons.Role of antibody dependent cell mediated cytotoxicity (ADCC) in Sm-p80-mediated protection against Schistosoma mansoni.Development of a schistosomiasis vaccine.Cross-species protection: Schistosoma mansoni Sm-p80 vaccine confers protection against Schistosoma haematobium in hamsters and baboons.Simultaneous priming with DNA encoding Sm-p80 and boosting with Sm-p80 protein confers protection against challenge infection with Schistosoma mansoni in mice.Pentalinonsterol, a Constituent of Pentalinon andrieuxii, Possesses Potent Immunomodulatory Activity and Primes T Cell Immune Responses.Adjuvant selection for vaccination against murine schistosomiasis.Cross-species prophylactic efficacy of Sm-p80-based vaccine and intracellular localization of Sm-p80/Sm-p80 ortholog proteins during development in Schistosoma mansoni, Schistosoma japonicum, and Schistosoma haematobium.The self-curing phenomenon of schistosome infection in rhesus macaques: insight from in vitro studies.Schistosoma Infection and Schistosoma-Derived Products Modulate the Immune Responses Associated with Protection against Type 2 Diabetes.
P2860
Q24598949-C12E3522-CC80-4770-BDA9-8DCEFF4701D5Q24635389-E13BBCFA-576C-46E9-9852-14078D6EF043Q27692376-F216EDD6-2987-42D3-AED5-13D2E2C1A44EQ34033792-A8F5E848-7104-4A94-8DB7-1DC4CFD1943CQ34079369-B5BC8CBB-9733-45A7-B63C-3EB2A38B3DEEQ36278786-1C199761-D05F-43C8-87A8-BCE6C46486FEQ36368518-DFA61586-962D-4CA4-95E6-A81002E65764Q37350747-650FCC13-2CD7-4FEA-A067-03C2A2DAFC38Q37603033-7708A1CE-99CE-452B-9820-0DE436432009Q39164396-FA4064C0-2D2D-47FA-8C7D-DD772FE82C17Q40065033-AFAAA7F2-58C3-41F9-AEAE-AB9C1FF4B758Q46223238-BF857DDB-2A68-47A0-93EA-DBC0A798EBE8Q46287356-C4DC4834-8BD5-4D9A-B410-ED9E98100F01Q47294803-05B19EC2-1FBD-4DD1-97C3-871D9001C3BFQ49539680-18D4DA90-0D29-4940-ADF9-D6247299EF91
P2860
Schistosoma mansoni antigen Sm-p80: Prophylactic efficacy of a vaccine formulated in human approved plasmid vector and adjuvant (VR 1020 and alum).
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Schistosoma mansoni antigen Sm ...... d adjuvant (VR 1020 and alum).
@ast
Schistosoma mansoni antigen Sm ...... d adjuvant (VR 1020 and alum).
@en
Schistosoma mansoni antigen Sm ...... ed plasmid vector and adjuvant
@nl
type
label
Schistosoma mansoni antigen Sm ...... d adjuvant (VR 1020 and alum).
@ast
Schistosoma mansoni antigen Sm ...... d adjuvant (VR 1020 and alum).
@en
Schistosoma mansoni antigen Sm ...... ed plasmid vector and adjuvant
@nl
prefLabel
Schistosoma mansoni antigen Sm ...... d adjuvant (VR 1020 and alum).
@ast
Schistosoma mansoni antigen Sm ...... d adjuvant (VR 1020 and alum).
@en
Schistosoma mansoni antigen Sm ...... ed plasmid vector and adjuvant
@nl
P2093
P2860
P1433
P1476
Schistosoma mansoni antigen Sm ...... d adjuvant (VR 1020 and alum).
@en
P2093
Afzal A Siddiqui
Weidong Zhang
Workineh Torben
P2860
P304
P356
10.1016/J.ACTATROPICA.2011.01.010
P577
2011-02-18T00:00:00Z